Skip to content
10-Q

Quarterly Report

Akebia Therapeutics, Inc. AKBA

0001517022-26-000039

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 4, 2026 268.26M sh
Shares Diluted Q1 2026 · Mar 31, 2026 267.05M sh
Shares Diluted Q1 2026 · Mar 31, 2025 241.6M sh
Capex Q1 2026 · Mar 31, 2026 $62K
Capex Q1 2026 · Mar 31, 2025 $18K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$21.21M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$13.59M
Long Term Debt Q1 2026 · Mar 31, 2026 $36.4M
Long Term Debt Q1 2026 · Dec 31, 2025 $48.25M
Short Term Debt Q1 2026 · Mar 31, 2026 $12.5M
Short Term Debt Q1 2026 · Dec 31, 2025 $0
Cash And Equivalents Q1 2026 · Mar 31, 2026 $162.64M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $184.84M
Stockholders Equity Q1 2026 · Mar 31, 2026 $27.38M
Stockholders Equity Q1 2026 · Dec 31, 2025 $32.61M
Stockholders Equity Q1 2026 · Mar 31, 2025 $24.58M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$49.19M
Current Liabilities Q1 2026 · Mar 31, 2026 $173.88M
Current Liabilities Q1 2026 · Dec 31, 2025 $162.94M
Total Liabilities Q1 2026 · Mar 31, 2026 $335.15M
Total Liabilities Q1 2026 · Dec 31, 2025 $343.96M
Current Assets Q1 2026 · Mar 31, 2026 $243.48M
Current Assets Q1 2026 · Dec 31, 2025 $252.96M
Total Assets Q1 2026 · Mar 31, 2026 $362.52M
Total Assets Q1 2026 · Dec 31, 2025 $376.57M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.03
Eps Diluted Q1 2026 · Mar 31, 2025 $0.03
Eps Basic Q1 2026 · Mar 31, 2026 −$0.03
Eps Basic Q1 2026 · Mar 31, 2025 $0.03
Sga Expense Q1 2026 · Mar 31, 2026 $30.44M
Sga Expense Q1 2026 · Mar 31, 2025 $25.74M
Rd Expense Q1 2026 · Mar 31, 2026 $14.81M
Rd Expense Q1 2026 · Mar 31, 2025 $9.75M
Net Income Q1 2026 · Mar 31, 2026 −$9.05M
Net Income Q1 2026 · Mar 31, 2025 $6.11M
Operating Income Q1 2026 · Mar 31, 2026 −$4.7M
Operating Income Q1 2026 · Mar 31, 2025 $13.51M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $12.29M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $7.63M
Revenue Q1 2026 · Mar 31, 2026 $53.54M
Revenue Q1 2026 · Mar 31, 2025 $57.34M